Clinical Trials Directory

Trials / Completed

CompletedNCT01511965

Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Vitiligo is a depigmenting skin disease common. Vitiligo is caused by the disappearance of melanocytes in the epidermis. Vitiligo is the cause of disfigurement, psychological and social, that sounds a lot about the quality of life. Currently the standard treatment for vitiligo is ultraviolet ray (UV), but it only allows a 50% repigmentation of lesions in half of patients. The applications of autologous epidermal cells in the liquid phase is a promising new therapeutic approach of vitiligo. The main goal of this study is to compare prospectively the repigmentation of vitiligo lesions induced by application of autologous epidermal cells in liquid phase associated with light therapy and light therapy alone. Study's secondary goals: compare the applications of epidermal cells to phototherapy alone and phototherapy, in respect of: * Obtain a repigmentation\> 70% (threshold considered aesthetically relevant) * The occurrence of adverse events * Patient satisfaction regarding the efficacy and safety of treatment

Detailed description

MAIN CRITERIA * Rates of repigmentation of the vitiligo lesions to 12 months * The lesions of the layers defined by the investigator to Month 0, Month 3, Month 6 and Month 12 will be analyzed by an image analysis system managed by a computer. * Digital photos is taken in order to illustrate the quantitative results above. SECONDARY CRITERIA * Repigmentation\> 70% of the vitiligo lesions at 12 months * Rates of repigmentation of the vitiligo lesions at 12 months * Side effects: the frequency, severity and time of occurrence will be reported for each treatment. Side effects are classified into grades according to World Health Organization (WHO) criteria. * Patient satisfaction of the effectiveness and tolerance will be studied using visual analogue scales graded from 0 to 10.

Conditions

Interventions

TypeNameDescription
OTHERautologous (cellular therapy)The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.

Timeline

Start date
2011-05-01
Primary completion
2012-11-01
Completion
2012-11-01
First posted
2012-01-19
Last updated
2014-02-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01511965. Inclusion in this directory is not an endorsement.